

Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, Phase III ENHANCE Trial of prolonged-release fampridine

Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, Hupperts R, Blight AR, Englishby V, McNeill M, Chang I, Lima G, Elkins J.

CNS drugs

2019; 33(1):61-79

ARTICLE IDENTIFIERS

DOI: 10.1007/s40263-018-0586-5

PMID: 30535670

PMCID: not available

JOURNAL IDENTIFIERS

LCCN: not available

pISSN: 1172-7047

eISSN: 1179-1934

OCLC ID: not available

CONS ID: not available

US National Library of Medicine ID: not available

This article was identified from a query of the SafetyLit database.